Types of Lung Cancer: NSCLC, SCLC, and Rare Subtypes
Written by North Editorial Staff | Clinically reviewed by Laura Morrissey, RN, BSN | Last reviewed: February 2026
Introduction
Lung cancer is classified into several distinct types based on how cancer cells appear under a microscope and where they originate in the lungs. According to the American Cancer Society, understanding your specific type of lung cancer is crucial because treatment options, prognosis, and survival rates vary significantly depending on the classification. The two major categories are non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases, and small cell lung cancer (SCLC), which represents about 15% of cases. Within these broad categories exist several subtypes, each with unique characteristics and treatment considerations.
Your oncologist will determine your specific lung cancer type through examination of tissue samples collected during a biopsy or other diagnostic procedures. This classification process, combined with staging and biomarker testing, forms the foundation of your personalized treatment plan. Whether you're newly diagnosed or supporting a loved one, learning about the different types of lung cancer empowers you to ask informed questions and participate actively in treatment decisions.
This guide walks you through the major lung cancer classifications, explains how type influences treatment strategy, and highlights the importance of molecular profiling in modern cancer care. If you're exploring treatment options or considering clinical trials, understanding your lung cancer type is the essential first step.
Non-Small Cell Lung Cancer (NSCLC)
Non-small cell lung cancer comprises the majority of lung cancer diagnoses and includes several histological subtypes. Each subtype arises from different cell types within the lungs and may present with distinct characteristics regarding location, risk factors, and treatment response.
Adenocarcinoma
Adenocarcinoma is the most common subtype of non-small cell lung cancer, accounting for approximately 40% of all lung cancer cases. Unlike other lung cancer types, adenocarcinoma is more frequently diagnosed in non-smokers and shows a slight predominance in women. This subtype typically arises in the peripheral regions of the lungs — the outer areas away from the central airways — making early detection sometimes more challenging.
Adenocarcinoma develops from the mucus-secreting glandular cells that line the airways. Because it tends to grow more slowly than some other lung cancer subtypes, some cases may be detected at an earlier stage. However, adenocarcinoma is also frequently diagnosed in younger patients and has been rising in incidence over recent decades, even as overall smoking rates decline.
The treatment landscape for adenocarcinoma has expanded significantly with advances in targeted therapy and biomarker testing. Many adenocarcinomas harbor specific genetic mutations, such as EGFR or ALK alterations, that make them candidates for precision treatment approaches. For more detailed information about adenocarcinoma specifically, including symptom recognition and management strategies, visit our dedicated resource on adenocarcinoma lung cancer.
Squamous Cell Carcinoma
Squamous cell carcinoma accounts for approximately 25-30% of non-small cell lung cancer cases. This subtype arises from flat, scale-like cells (squamous cells) that line the airways. Squamous cell carcinoma has a strong association with cigarette smoking and typically develops in the central airways — the larger bronchi closer to the center of the lungs.
Because squamous cell carcinomas originate in central airway locations, they may produce symptoms earlier than peripheral tumors, such as cough or airway obstruction. The central location also means these tumors may be more accessible for certain diagnostic procedures and interventions. Historically, squamous cell carcinoma was the most common type of lung cancer in the United States, but its prevalence has declined as smoking rates have dropped.
Treatment for squamous cell carcinoma has traditionally relied on chemotherapy and radiation, though immunotherapy approaches are becoming increasingly important in the treatment arsenal. Unlike adenocarcinoma, squamous cell carcinoma is less frequently associated with targetable genetic mutations, making it an area of active research in clinical trial development.
Large Cell Carcinoma
Large cell carcinoma is the least common subtype of non-small cell lung cancer, representing approximately 10-15% of NSCLC cases. This type is characterized by large cells with abundant cytoplasm that lack the specific features of adenocarcinoma or squamous cell carcinoma. Because large cell carcinoma lacks these distinguishing characteristics, it's sometimes identified only after other subtypes have been ruled out.
Large cell carcinoma can develop anywhere in the lungs, both centrally and peripherally. A notable characteristic is that this subtype tends to grow and spread relatively quickly compared to some other NSCLC types. This aggressive growth pattern often means these tumors may have progressed to advanced stages by the time of diagnosis, which influences treatment recommendations and prognosis.
Treatment approaches for large cell carcinoma typically follow non-small cell lung cancer protocols, often involving chemotherapy, radiation, or surgery depending on stage and patient factors. Because of its relative rarity and aggressive nature, large cell carcinoma cases may be particularly well-suited for evaluation in clinical trial settings where novel treatment combinations are being tested.
Small Cell Lung Cancer (SCLC)
Small cell lung cancer represents approximately 15% of all lung cancer diagnoses and differs significantly from NSCLC in terms of biology, behavior, and treatment approach. This type is characterized by small, round cells that grow very rapidly and have a strong tendency to spread to distant sites early in disease progression.
Small cell lung cancer has an extremely strong association with cigarette smoking, with more than 95% of cases occurring in current or former smokers. This tight link to smoking history reflects the fact that SCLC arises from neuroendocrine cells within the airways and tends to be highly aggressive. By the time many SCLC cases are diagnosed, the cancer has already spread beyond the lungs.
Medical professionals often classify SCLC into two stages: limited-stage disease (cancer confined to the lungs and nearby lymph nodes) and extensive-stage disease (cancer that has spread to distant organs or the opposite lung). This two-stage system differs from the TNM staging used for NSCLC and reflects the more uniform, aggressive nature of SCLC.
Treatment for small cell lung cancer differs markedly from NSCLC approaches. Chemotherapy combined with thoracic radiation therapy remains the cornerstone of treatment, particularly for limited-stage disease. Immunotherapy agents are increasingly being incorporated into SCLC treatment regimens, offering new hope for improved outcomes. Surgery plays a limited role, typically reserved for specific limited-stage cases. The treatment intensity is generally high, reflecting the aggressive biology of this cancer type, and many patients receive chemotherapy in combination with radiation to address both local and systemic disease.
Rare Lung Cancer Types
In addition to the common adenocarcinoma, squamous cell, and large cell categories, several rarer lung cancer subtypes exist. While these account for a smaller percentage of overall lung cancer cases, they warrant distinct consideration for diagnosis and treatment.
Carcinoid Tumors
Carcinoid tumors are slow-growing neuroendocrine tumors that arise from hormone-producing cells in the lungs. These tumors are classified into two categories: typical carcinoid and atypical carcinoid. Typical carcinoid tumors are very slow-growing with an excellent prognosis when diagnosed early. Atypical carcinoid tumors grow somewhat faster than typical carcinoid and have a less favorable prognosis, though still better than many other lung cancer types.
Carcinoid tumors tend to arise in the central airways and may not cause symptoms until they reach a significant size or obstruct an airway. Because of their slow growth and often peripheral location within major airways, some carcinoid tumors are detected incidentally on imaging performed for other reasons. Surgery is often the primary treatment for carcinoid tumors, and many patients have excellent long-term outcomes.
Adenosquamous Carcinoma
Adenosquamous carcinoma is a rare hybrid tumor containing both glandular (adenocarcinoma) and squamous cell components. This subtype represents less than 5% of lung cancers and tends to be more aggressive than either adenocarcinoma or squamous cell carcinoma alone. Adenosquamous tumors are typically discovered at an advanced stage and are associated with a less favorable prognosis.
Sarcomatoid Carcinoma
Sarcomatoid carcinoma is an uncommon subtype characterized by spindle-shaped or pleomorphic cells that resemble soft tissue sarcomas. This rare type is highly aggressive and prone to early dissemination. Sarcomatoid carcinoma comprises less than 3% of lung cancers but requires aggressive multimodal treatment and carries a worse prognosis than typical NSCLC.
Large Cell Neuroendocrine Carcinoma
Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung cancer subtype with neuroendocrine characteristics. Though classified within the NSCLC category, LCNEC behaves more similarly to small cell lung cancer in terms of growth rate and early spread. This aggressive behavior often requires treatment approaches more intensive than typical NSCLC protocols.
How Lung Cancer Type Affects Treatment
Your specific lung cancer type is fundamental to determining which treatments may be most effective for you. The treatment landscape differs substantially between NSCLC and SCLC, and even within NSCLC, subtype influences certain treatment decisions.
NSCLC Treatment Approaches
For non-small cell lung cancer, treatment options depend on stage, biomarker profile, and overall health status. Early-stage NSCLC may be managed with surgery alone, while advanced stages typically require chemotherapy, targeted therapy, immunotherapy, or combinations thereof. The specific chemotherapy drugs used may vary slightly by subtype — for instance, certain drugs have shown particular efficacy in squamous cell carcinoma.
Targeted therapy is a cornerstone of modern NSCLC treatment. These medications are designed to attack cancer cells with specific genetic mutations or protein expressions. Because adenocarcinoma commonly harbors targetable mutations (such as EGFR, ALK, or ROS1), patients with these mutations may benefit significantly from targeted therapy approaches. Squamous cell and large cell carcinomas are less frequently associated with common targetable mutations, though testing is still important.
SCLC Treatment Approaches
Small cell lung cancer treatment is more standardized than NSCLC because SCLC is highly chemosensitive. The traditional backbone has been platinum-based chemotherapy (cisplatin or carboplatin) combined with etoposide, often paired with thoracic radiation for limited-stage disease. More recently, immunotherapy drugs have been added to chemotherapy regimens, improving survival outcomes for some patients.
Because SCLC spreads early and aggressively, treatment is intensive and often requires hospitalization or frequent visits. Prophylactic cranial radiation may be considered to prevent brain metastases, which are common in SCLC. The approach is markedly different from NSCLC, emphasizing systemic treatment over surgery in most cases.
The Role of Biomarker Testing
Biomarker testing — also called molecular profiling or genetic testing — has revolutionized lung cancer treatment by enabling precision medicine approaches. Your biomarker results help your oncologist select the most effective treatments with the fewest side effects.
Common Biomarkers in NSCLC
The most commonly tested biomarkers in adenocarcinoma and other NSCLC types include:
EGFR mutations: Found in approximately 15-20% of NSCLC cases in the U.S. (higher in Asian populations), EGFR mutations predict excellent response to targeted therapy with EGFR inhibitors.
ALK rearrangements: Present in 2-5% of NSCLC cases, ALK-positive tumors respond dramatically to ALK inhibitors.
ROS1 rearrangements: Found in 1-2% of cases, ROS1-positive tumors are highly sensitive to ROS1 inhibitors.
PD-L1 expression: This biomarker predicts response to immunotherapy agents and helps guide treatment selection.
KRAS mutations: Present in 25-30% of adenocarcinomas, KRAS
mutations have historically indicated less favorable prognosis,
though new targeted agents are emerging.
BRAF mutations: Found in approximately 2-3% of cases, some BRAF mutations are actionable with targeted therapies.
Testing Methods
Biomarker testing typically uses tissue obtained during biopsy or surgery. Advanced techniques like next-generation sequencing (NGS) can analyze multiple genes simultaneously, providing comprehensive insights into your tumor's genetic profile. Some testing may also be performed on blood samples (liquid biopsy), which is becoming increasingly available.
The results of biomarker testing directly influence treatment decisions and may open doors to clinical trials testing novel agents targeting specific mutations. This is why comprehensive testing at diagnosis is so important — it ensures you receive the most personalized, effective treatment possible.
Clinical Trials by Lung Cancer Type
The landscape of available clinical trials varies considerably depending on your specific lung cancer type. Understanding what trials might be available to you can expand your treatment options and potentially provide access to cutting-edge therapies.
NSCLC Trials
Non-small cell lung cancer has the most robust clinical trial landscape, with thousands of active studies worldwide. Trials are available for:
Adenocarcinoma with specific mutations (EGFR, ALK, ROS1, KRAS mutations)
Treatment-naive patients seeking novel chemotherapy combinations
Immunotherapy combinations addressing different patient populations
Patients with resistance to targeted therapy or immunotherapy
Early-stage disease exploring adjuvant (post-surgical) treatment approaches
Advanced disease testing novel maintenance strategies
Because adenocarcinoma is the most common subtype and occurs in diverse patient populations (smokers and non-smokers, younger and older patients), it has extensive trial representation.
SCLC Trials
Small cell lung cancer clinical trial availability has expanded significantly in recent years as immunotherapy agents have shown promise. Active trials typically focus on:
Novel chemotherapy combinations
Immunotherapy + chemotherapy regimens
Treatment approaches for recurrent or resistant SCLC
Prophylactic cranial radiation timing and approaches
Agents targeting specific genetic alterations in SCLC
To explore clinical trials that may be appropriate for your specific diagnosis and situation, visit North's comprehensive lung cancer clinical trials finder.
Key Takeaways
Lung cancer is classified into major types — NSCLC and SCLC — based on cell appearance and origin. Understanding your specific type is essential for treatment planning and prognosis assessment.
NSCLC accounts for 85% of cases and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype has distinct characteristics regarding location, risk factors, and treatment response.
Adenocarcinoma is the most common lung cancer type and increasingly occurs in non-smokers. It often has targetable mutations that enable precision treatment approaches.
SCLC represents 15% of cases and is highly aggressive with strong smoking association. This type requires intensive chemotherapy and often radiation, with immunotherapy increasingly incorporated.
Rare lung cancer types include carcinoid, adenosquamous, sarcomatoid, and large cell neuroendocrine carcinoma. These subtypes require specialized knowledge and may benefit from clinical trial evaluation.
Biomarker testing is critical for NSCLC treatment selection, identifying mutations and protein expressions that predict response to targeted therapy and immunotherapy.
Frequently Asked Questions
What is the most common type of lung cancer?
Adenocarcinoma is the most common lung cancer subtype, accounting for approximately 40% of all cases. It's notable for occurring more frequently in non-smokers and women compared to other types. Adenocarcinoma typically develops in the peripheral (outer) regions of the lungs and often grows more slowly than some other subtypes, which can lead to earlier detection in some cases.
What's the difference between NSCLC and SCLC?
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) differ in several important ways. NSCLC, accounting for 85% of cases, grows more slowly and is often diagnosed earlier. Treatment may include surgery, chemotherapy, targeted therapy, or immunotherapy depending on stage and biomarkers. SCLC, representing 15% of cases, grows rapidly and spreads early. It's treated primarily with intensive chemotherapy and radiation, with surgery rarely used. SCLC has a strong smoking association, while NSCLC now occurs frequently in non-smokers.
How do doctors determine my lung cancer type?
Your lung cancer type is determined through examination of tissue cells obtained during a biopsy (needle biopsy, bronchoscopy, or surgical sampling) or tumor tissue from surgery. Pathologists examine the cells under a microscope to identify their characteristics. Additional tests like immunohistochemistry and biomarker testing provide further classification details. Your oncologist uses this information along with imaging studies to determine your precise diagnosis and stage.
Are there targeted treatments for my lung cancer type?
This depends on your specific type and biomarker results. Adenocarcinoma frequently harbors targetable mutations (EGFR, ALK, ROS1, KRAS) that respond to targeted therapy drugs. Squamous cell and large cell carcinomas are less likely to have common targetable mutations, though testing is still important. Immunotherapy may benefit patients with certain biomarker profiles across all NSCLC subtypes. SCLC rarely has actionable mutations but may respond to emerging targeted approaches. Your oncologist will discuss what options apply to your specific case based on your biomarker testing results.
Can clinical trials help me based on my lung cancer type?
Yes, clinical trials may offer additional options depending on your specific type, stage, and biomarker profile. NSCLC has extensive trial availability across all subtypes and at various treatment stages. SCLC trials have expanded significantly, particularly testing immunotherapy approaches. Rare lung cancer types may benefit from trials exploring novel treatment combinations. North's clinical trials finder helps you search for trials matching your specific diagnosis and treatment history.
References
American Cancer Society. (2026). Key Statistics for Lung Cancer. https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
National Cancer Institute. (2025). Non-Small Cell Lung Cancer Treatment (Adult) — Patient Version. PDQ. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
National Comprehensive Cancer Network. (2026). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2026. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
Hendriks, L. E., Kerr, K. M., Menis, J., et al. (2023). Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 358–376. https://pubmed.ncbi.nlm.nih.gov/36669645/
Khurshid, H., Ismaila, N., Das, M., et al. (2025). Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. JCO Oncology Practice, 21(6), 754–758. https://pubmed.ncbi.nlm.nih.gov/39565981/
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553(7689), 446–454. https://pubmed.ncbi.nlm.nih.gov/29364287/
WHO Classification of Tumours Editorial Board. (2021). Thoracic Tumours (5th ed.). International Agency for Research on Cancer. https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021
